Dr. Kizil and his team at Columbia University Medical Center in New York City will develop a first-in-class precision therapy that targets accumulation of the protein fibronectin and subsequent neuroinflammation at its source before irreversible damage and cognitive decline occur. This therapy could offer safer, genetically informed, and personalized treatment options for patients carrying the APOE-ε4 allele, which is the strongest genetic risk factor for Alzheimer’s disease.
Caghan Kizil, PhD was awarded a #CureOneCureMany Catalyst Award in #Neuroinflammation.
Institution: @columbiauniversity.bsky.social
This $500K award is funded with the National MS Society, Gates Ventures, NFL Players Association, Genentech, and WoodNext Foundation.
buff.ly/DbqbFwN